OR WAIT null SECS
March 18, 2024
In a non-exclusive licensing agreement, Ricoh will have access to ERS Genomics’ CRISPR/Cas9 genome editing technology to create novel disease models.
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
The company is investing more than $2 million in its analytical testing services and adding suppository manufacturing capabilities.
March 12, 2024
The Italian company’s North American business has seen an increase of 47%.
March 06, 2024
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 01, 2024
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
February 21, 2024
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.